Enterprise Value
63.57M
Cash
12.04M
Avg Qtr Burn
-6.124M
Short % of Float
5.66%
Insider Ownership
68.95%
Institutional Own.
2.26%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ACG-701 Details Cystic fibrosis | Phase 2 Data readout | |
ACG-701 Details Melioidosis | Phase 2 Data readout | |
ACG-801 Details Farber Disease | Phase 2 Initiation | |
Tilsotolimod (tilsotolimod + ipilimumab/ nivolumab) Details Colorectal cancer , Cancer, Solid tumor/s | Failed Discontinued | |
Tilsotolimod (IMO-2125 + ipilimumab) Details Melanoma, Cancer | Failed Discontinued |